Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) Operating Income: 2019-2024

Historic Operating Income for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$23.2 million.

  • GeneDx Holdings' Operating Income rose 58.21% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 117.28%. This contributed to the annual value of -$23.2 million for FY2024, which is 87.15% up from last year.
  • According to the latest figures from FY2024, GeneDx Holdings' Operating Income is -$23.2 million, which was up 87.15% from -$180.6 million recorded in FY2023.
  • GeneDx Holdings' Operating Income's 5-year high stood at -$23.2 million during FY2024, with a 5-year trough of -$667.7 million in FY2022.
  • Moreover, its 3-year median value for Operating Income was -$180.6 million (2023), whereas its average is -$290.5 million.
  • As far as peak fluctuations go, GeneDx Holdings' Operating Income slumped by 695.69% in 2020, and later spiked by 87.15% in 2024.
  • Yearly analysis of 5 years shows GeneDx Holdings' Operating Income stood at -$242.0 million in 2020, then tumbled by 84.36% to -$446.1 million in 2021, then crashed by 49.65% to -$667.7 million in 2022, then skyrocketed by 72.95% to -$180.6 million in 2023, then skyrocketed by 87.15% to -$23.2 million in 2024.